- Home
- EPRX vs CHRS Comparison
EPRX vs CHRS Comparison
Compare EPRX & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPRX
- CHRS
- Stock Information
- Founded
- EPRX 2011
- CHRS 2010
- Country
- EPRX Canada
- CHRS United States
- Employees
- EPRX N/A
- CHRS 228
- Industry
- EPRX
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EPRX
- CHRS Health Care
- Exchange
- EPRX NYSE
- CHRS Nasdaq
- Market Cap
- EPRX 111.1M
- CHRS 122.9M
- IPO Year
- EPRX N/A
- CHRS 2014
- Fundamental
- Price
- EPRX $3.85
- CHRS $1.15
- Analyst Decision
- EPRX Strong Buy
- CHRS Strong Buy
- Analyst Count
- EPRX 1
- CHRS 4
- Target Price
- EPRX $9.00
- CHRS $5.38
- AVG Volume (30 Days)
- EPRX 8.8K
- CHRS 1.9M
- Earning Date
- EPRX 05-07-2025
- CHRS 05-08-2025
- Dividend Yield
- EPRX N/A
- CHRS N/A
- EPS Growth
- EPRX N/A
- CHRS N/A
- EPS
- EPRX N/A
- CHRS 0.25
- Revenue
- EPRX N/A
- CHRS $266,959,999.00
- Revenue This Year
- EPRX N/A
- CHRS N/A
- Revenue Next Year
- EPRX N/A
- CHRS $9.02
- P/E Ratio
- EPRX N/A
- CHRS $4.34
- Revenue Growth
- EPRX N/A
- CHRS 3.78
- 52 Week Low
- EPRX $2.20
- CHRS $0.66
- 52 Week High
- EPRX $4.48
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- EPRX N/A
- CHRS 62.10
- Support Level
- EPRX N/A
- CHRS $0.72
- Resistance Level
- EPRX N/A
- CHRS $1.14
- Average True Range (ATR)
- EPRX 0.00
- CHRS 0.09
- MACD
- EPRX 0.00
- CHRS 0.04
- Stochastic Oscillator
- EPRX 0.00
- CHRS 102.40
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.